v3.20.2
STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (36,330) $ (15,675)
Reconciliation of net loss to net cash used in operating activities    
Depreciation and amortization 95 122
Stock-based compensation expense 2,732 1,712
Changes in operating assets and liabilities:    
Prepaid expenses and other assets (1,137) (1,009)
Accounts payable, accrued expenses and other 7,663 3,153
Net cash used in operating activities (26,977) (11,697)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of equipment and leasehold improvements (51) (825)
Net cash used in investing activities (51) (825)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of common stock, net of issuance costs 68,811 230
Purchase and cancellation of shares from BioXcel Corporation (9,024)  
Deferred offering expense   (378)
Due to Parent   69
Exercise of options 310 1
Net cash provided by financing activities 60,097 (78)
Net (decrease) increase in cash and cash equivalents 33,069 (12,600)
Cash and cash equivalents, beginning of the period 32,426 42,565
Cash and cash equivalents, end of the period 65,495 29,965
Supplemental cash flow information:    
Interest paid $ 18 $ 29

Source